RE: Flat-lined9 Aug 2022 20:28
Kaerens text nearly all translated
The Diagnostic BU will be unified from trade to marketing via R&D and production under the direction of Thierry Paper, Deputy Chief Executive Officer.
"Biosynex played a major role during the COVID-19 crisis by providing innovative diagnostic solutions to various health professionals. We are now projecting ourselves as a reference French player in different segments of in vitro diagnosis: rapid tests, molecular biology, delocalised biology (Point of care) and monitoring of biotherapies. To achieve our objectives, we are committed to a proactive innovation policy by strengthening our Research & Development capacities and multiplying strategic partnerships and external growth. At the same time, we are expanding our sales network through the creation of subsidiaries or the acquisition of distributors. The metamorphosis of Biosynex into a multinational medtech is underway. This evolution has led us to adapt our internal organisation by creating two poles: diagnosis and pharmacy. Personally, I am honoured to expand my responsibilities and take over the management of the Diagnostic division 17 years after founding this company with Larry Abensur and Thomas Lamy. I will ensure the fulfilment of everyone in a mature structure but who has kept his youth and his desire to go from